Clinical trials: ABDOMINAL SUBCUTANEOUS FAT, open to volunteers
Overweight and Obesity, Metabolic Syndrome
Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding
Adipose, or fat, tissue is a plastic organ that retains the ability to expand and store excess calories during positive energy balance in humans.
- Trial name
- EAT 2 (NCT04583514)
- Testing
- Control, Overfeeding
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Pennington Biomedical Research Center
Subcutaneous Fat
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
- Trial name
- NCT07608757
- Testing
- CBL-514 Injection
- Where
- Australia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Non-Alcoholic Fatty Liver Disease, Obesity, Morbid
Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
The study is aimed To quantify the change of adipose tissues, triglyceride in liver and pancreas and cholesterol after lifestyle intervention or bariatric surgery.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Morbid, Brown Fat, Metabolic Disease
- Trial name
- NCT03875625
- Testing
- Bariatric surgery, Dietitian led life style modification intervention, Conventional care (control)
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Subcutaneous Fat
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
- Trial name
- SUPREME-01 (NCT07140939)
- Testing
- CBL-514 Injection, 0.9% Sodium Chloride
- Where
- 13 sites in United States, Canada
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Obesity, Type 2 Diabetes Mellitus
Radiomics of Intra-abdominal and Subcutaneous Adipose Tissue Predict the Efficacy of Bariatric Surgery (RISABS)
Using radiomics of intra-abdominal and subcutaneous adipose tissue and clinical features to predict the weight loss efficacy and remission of type 2 diabetes mellitus after bariatric surgery.
- Conditions
- Obesity, Type 2 Diabetes Mellitus, Bariatric Surgery
- Trial name
- NCT06169033
- Where
- China
- Volunteers
- 800 people
- Sponsor
- China-Japan Friendship Hospital
Subcutaneous Fat
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat
- Trial name
- NCT07608770
- Testing
- CBL-514 Injection, 0.9% Sodium Chloride
- Where
- Australia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
- Trial name
- NCT07526974
- Testing
- CBL-514 Injection, 0.9% Sodium Chloride
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
A Phase 3b, Multicenter, Two stage, Double-blind, Long term Follow up and Open-label Extension Study of Participants Who have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)
- Trial name
- NCT07733947
- Testing
- CBL-514 Injection, 0.9 % sodium chloride
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Respiratory Mechanics
Ultrasonographic Abdominal Fat Thickness and Driving Pressure During Prone Spinal Surgery
This prospective observational study aims to evaluate the association between preoperative abdominal subcutaneous fat thickness measured by ultrasonography and intraoperative driving pressure in adult patients undergoing elective…
- Trial name
- NCT07723690
- Volunteers
- 120 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey